Orforglipron
Orforglipron may reduce practical barriers associated with injectable incretin therapies. Participants assigned to orforglipron began at 12 mg once daily and escalated every four weeks to 36 mg or their maximum tolerated dose. Orforglipron…
1 sources - 5 claims
Orforglipron may reduce practical barriers associated with injectable incretin therapies. Participants assigned to orforglipron began at 12 mg once daily and escalated every four weeks to 36 mg or their maximum tolerated dose. Orforglipron is a once-daily nonpeptide oral GLP-1 receptor agonist being investigated for obesity and type 2 diabetes. Orforglipron can be taken without restrictions on food or water intake. Direct transition to 12 mg orforglipron after injectable incretin therapy was generally well tolerated.